Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients

Exclusion Criteria

• •Diagnosis of a nondermatophyte fungus infection, diagnosis of proximal subungual onychomycosis, diagnosis of superficial white onychomycosis
• •Diagnosis of peripheral arterial disease or anatomic abnormalities of the target toenail
• •Inability to follow through with all requisite office visits
• •Routine use of a systemic corticosteroid, routine use of a systemic immunomodulator, or history of systemic antifungals within the prior five years.
• •Active interdigital tinea pedis refractory to topical antifungal treatments
• •Known hypersensitivity to efinaconazole
• •Use, within the month preceding screening, of: topical antifungal agents, topical anti-inflammatory agents to the toes
• •Any history of oral systemic antifungal with known activity against dermatophytes